Kuang Tien General Hospital   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Taichung Taiwan (1913)

Organization Overview

First Clinical Trial
2007
NCT01014221
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Kuang Tien General Hospital | Kuang Tien Genreal Hospital | Neurology department of Kuang Tien General hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

cilostazol (pletal) (1 trial)

Drugs in Phase 2 Trials (1)

astragalus membranaceus (1 trial)

Drugs in Other Trials (5)

omega-3 fatty acids (Omacor) (1 trial)

omega-6 fatty acids (1 trial)

prednisone (meticorten) (1 trial)

topiramate (topamax) (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 4)

Ischemia (Phase 4)

Peripheral Arterial Disease (Phase 4)

Peripheral Vascular Diseases (Phase 4)

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7